Mark A. Buthman
Known title: DirectorCIK: 0001223783
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
Transaction History
| IEX | ▲ Buy | Grant | 805 | $0 | 5/6/2026 | View on chart |
| WST | ▲ Buy | Grant | 791 | $0 | 5/4/2026 | View on chart |
| IEX | ▲ Buy | Grant | 895 | $0 | 5/8/2025 | View on chart |
| WST | ▲ Buy | Grant | 1,071 | $0 | 5/6/2025 | View on chart |
| IEX | ▲ Buy | Grant | 745 | $0 | 5/7/2024 | View on chart |
| WST | ▲ Buy | Grant | 564 | $0 | 4/23/2024 | View on chart |
| IEX | ▲ Buy | Grant | 770 | $0 | 5/25/2023 | View on chart |
| WST | ▲ Buy | Grant | 616 | — | 4/25/2023 | View on chart |
| WST | ▲ Buy | Grant | 632 | — | 5/24/2022 | View on chart |
| IEX | ▲ Buy | Grant | 825 | $0 | 5/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IDEX price target raised to $285 by RBC Capital
RBC Capital has kept its outperform rating on IDEX and lifted the target price to $285, reflecting confidence in the company's earnings outlook. The move comes as the stock trades near the upper end of its 52‑week range and shows a moderately strong RSI of 63.3. Analysts see the firm’s valuation as still attractive compared to peers. The update may influence how investors view IDEX’s growth prospects.
IDEX price target raised to $285 by RBC Capital. RBC Capital has kept its outperform rating on IDEX and lifted the target price to $285, reflecting confidence in the company's earnings outlook. The move comes as the stock trades near the upper end of its 52‑week range and shows a moderately strong RSI of 63.3. Analysts see the firm’s valuation as still attractive compared to peers. The update may influence how investors view IDEX’s growth prospects.